Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2016, specifically dated December 21, 2016. The company is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing reports a specific cash inflow event but does not provide comprehensive financial statements for the period.
- Cash Flow: Received a payment of $500,000 from Chong Kun Dang Pharmaceuticals ("CKD").
- Revenue: The filing does not explicitly state total revenue for the period, though the $500,000 payment is noted as the first under a distribution agreement.
- Profit, Margins, Debt, Liquidity: The filing text does not provide clear values for net income, operating margins, total debt, or overall liquidity positions.
Material Changes
The primary material change reported is the execution of a commercial milestone: the receipt of the first payment under a previously entered distribution agreement with CKD. No comparative financial data versus prior periods is included in this specific report.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the CKD payment. The filing does not contain updated financial guidance, forward-looking outlooks, specific risk factors, or details on contingencies beyond the referenced press release.
Investor Verification Checklist
- Verify the total value and payment schedule of the distribution agreement with Chong Kun Dang Pharmaceuticals.
- Confirm the accounting treatment of the $500,000 payment (e.g., revenue recognition timing) in the next quarterly or annual report.
- Review the full text of the attached press release (Exhibit 99.1) for additional commercial terms not detailed in the Form 6-K summary.
- Check subsequent filings for updated cash position and liquidity metrics following this payment.